4-[3-(3-Pyridylcarbonyl)phenyl]butanol | 442912-97-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[3-(3-Pyridylcarbonyl)phenyl]butanol
• 英文别名: [3-(4-hydroxybutyl)phenyl]-pyridin-3-ylmethanone
• CAS: 442912-97-2
• 化学式: C₁₆H₁₇NO₂
• 分子量: 255.316
• InChiKey: IWFKITFSQNHOEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[3-(3-Pyridylcarbonyl)phenyl]butanol 在 potassium permanganate 作用下， 以 水 为溶剂， 以55%的产率得到4-[3-(3-Pyridylcarbonyl)phenyl]butyric Acid
  参考文献：
  名称：

  Novel Agents Combining Platelet Activating Factor (PAF) Receptor Antagonist with Thromboxane Synthase Inhibitor (TxSI)

  摘要：

  Compounds 1 or 2 which possess dual-acting PAF antagonist/TxSI in a previous paper were modified and evaluated for the dual-acting activity. It was found that several compounds were potent dual-acting PAF antagonist/TxSI in and ex vivo. 6-(2-Chlorophenyl)-3-[4-[(E /Z)-6-ethoxvcarbonyl-1-(3-pyridyl)-1-hexenyl]phenylmethyl]-8,11-dimethyl-2,3.4,5-tetrahydro-8H-pyrido[4',3': 4.5]thieno[3.2-f][1,2,4]triazolo[4,3-a][1.4]diazepine (12) is excellent orally dual-acting PAF antagonist/TxSI. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00005-7
• 作为产物：
  描述：

  2-羧乙基三苯基溴化磷 在 palladium on activated charcoal 咪唑 、 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 正丁基锂 、 氯化亚砜 、 potassium tert-butylate 、 四丁基氟化铵 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[3-(3-Pyridylcarbonyl)phenyl]butanol
  参考文献：
  名称：

  Novel Agents Combining Platelet Activating Factor (PAF) Receptor Antagonist with Thromboxane Synthase Inhibitor (TxSI)

  摘要：

  Compounds 1 or 2 which possess dual-acting PAF antagonist/TxSI in a previous paper were modified and evaluated for the dual-acting activity. It was found that several compounds were potent dual-acting PAF antagonist/TxSI in and ex vivo. 6-(2-Chlorophenyl)-3-[4-[(E /Z)-6-ethoxvcarbonyl-1-(3-pyridyl)-1-hexenyl]phenylmethyl]-8,11-dimethyl-2,3.4,5-tetrahydro-8H-pyrido[4',3': 4.5]thieno[3.2-f][1,2,4]triazolo[4,3-a][1.4]diazepine (12) is excellent orally dual-acting PAF antagonist/TxSI. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00005-7

文献信息

• Triazolo-1,4-diazepine compounds and medicinal composition containing the same
  申请人：Nikken Chemicals Co., Ltd.

  公开号：US06433167B1

  公开（公告）日：2002-08-13

  A triazolo-1,4-diazepine compound having the formula (I): wherein A represents CO, CO—B, or B, B represents a C1 to C6 alkylene group or a C2 to C6 alkylene group having an oxygen atom interposed in the middle thereof, X represents N—O or CH, n represents an integer of 2 to 6, R represents a hydroxyl group, a C1 to C6 lower alkyloxy group or a C1 to C6 lower alkylamino group, provided that these groups may be substituted with an N,N-dimethylamino group, an N,N-diethylamino group, a phenyl group, or a heterocyclic group, and R1 represents a hydrogen atom or a C1 to C3 lower alkyl group having both a PAF antagonistic action and a thromboxane synthesis inhibiting action, and a pharmaceutical composition containing the same as an active ingredient.

  一种具有以下式子（I）的三唑并[1,4]二氮杂环化合物： 其中A代表CO，CO-B或B，B代表C1到C6烷基或在其中间有氧原子的C2到C6烷基，X代表N-O或CH，n代表2到6的整数，R代表羟基，C1到C6低烷氧基或C1到C6低烷基氨基，但这些基团可以被N，N-二甲基氨基，N，N-二乙基氨基，苯基或杂环基所取代，并且R1代表氢原子或具有PAF拮抗作用和血栓素合成抑制作用的C1到C3低烷基，以及包含该化合物作为活性成分的药物组合物。
• TRIAZOLO-1,4-DIAZEPINE COMPOUNDS AND MEDICINAL COMPOSITION CONTAINING THE SAME
  申请人：Nikken Chemicals Company, Limited

  公开号：EP0995752A1

  公开（公告）日：2000-04-26

  A triazolo-1,4-diazepine compound having the formula (I): wherein A represents CO, CO-B, or B, B represents a C1 to C6 alkylene group or a C2 to C6 alkylene group having an oxygen atom interposed in the middle thereof, X represents N-O or CH, n represents an integer of 2 to 6, R represents a hydroxyl group, a C1 to C6 lower alkyloxy group or a C1 to C6 lower alkylamino group, provided that these groups may be substituted with an N,N-dimethylamino group, an N,N-diethylamino group, a phenyl group, or a heterocyclic group, and R1 represents a hydrogen atom or a C1 to C3 lower alkyl group having both a PAF antogonistic action and a thromboxane synthesis inhibiting action, and a pharmaceutical composition containing the same as an active ingredient.

  一种具有式 (I) 的三唑并-1,4-二氮杂卓化合物： 其中 A 代表 CO、CO-B 或 B，B 代表 C1 至 C6 亚烷基或中间含有一个氧原子的 C2 至 C6 亚烷基，X 代表 N-O 或 CH，n 代表 2 至 6 的整数，R 代表羟基、C1 至 C6 低级烷氧基或 C1 至 C6 低级烷基氨基、但这些基团可被 N,N-二甲基氨基基团、N,N-二乙基氨基基团、苯基或杂环基团取代，R1 代表氢原子或同时具有 PAF 拮抗作用和血栓素合成抑制作用的 C1 至 C3 低级烷基，以及含有这些基团作为活性成分的药物组合物。
• US6433167B1
  申请人：——

  公开号：US6433167B1

  公开（公告）日：2002-08-13
• Novel Agents Combining Platelet Activating Factor (PAF) Receptor Antagonist with Thromboxane Synthase Inhibitor (TxSI)
  作者：Masakazu Fujita、Taketsugu Seki、Haruaki Inada、Kazuhiro Shimizu、Akane Takahama、Tetsuro Sano

  DOI：10.1016/s0960-894x(02)00005-7

  日期：2002.3

  Compounds 1 or 2 which possess dual-acting PAF antagonist/TxSI in a previous paper were modified and evaluated for the dual-acting activity. It was found that several compounds were potent dual-acting PAF antagonist/TxSI in and ex vivo. 6-(2-Chlorophenyl)-3-[4-[(E /Z)-6-ethoxvcarbonyl-1-(3-pyridyl)-1-hexenyl]phenylmethyl]-8,11-dimethyl-2,3.4,5-tetrahydro-8H-pyrido[4',3': 4.5]thieno[3.2-f][1,2,4]triazolo[4,3-a][1.4]diazepine (12) is excellent orally dual-acting PAF antagonist/TxSI. (C) 2002 Elsevier Science Ltd. All rights reserved.